SHANGHAI, SHANGHAI, CHINA, April 30, 2026 /EINPresswire.com/ -- In today’s life sciences industry, moving a drug ...

Drug discovery still too often relies on expensive trial and error. Researchers from ICTER show there is another way—building ...

Continuous process improvement can benefit all aspects of life — from personal New Year’s resolutions to complex drug development. In a world where two-thirds of planned improvement initiatives fail, ...

Discover how quality-driven drug development and AI accelerate safer medicines, reduce risk, and improve patient outcomes.

Accelerated drug development expertise. For small startups and academic spinoffs bringing their first molecules to market, ...

From survivorship bias to root causes! Researchers have applied AI and machine learning to every stage of the drug development process. This includes identifying targets in the body, screening ...

The U.S. Food and Drug Administration (FDA) announced a new process called “Rare Disease Evidence Principles” (RDEP), under which eligible drugs and biologics for ultra-rare diseases caused by known ...

The potential of using artificial intelligence in drug discovery and development has sparked both excitement and skepticism among scientists, investors, and the general public. Researchers have ...

The goal of this collaborative was to examine the contributing factors towards the failure of late-stage clinical product development and develop key considerations for stakeholders to improve the ...

When we treat cancer patients, their disease can overcome treatment through its innate capacity to adapt. This is at the ...

The FDA has granted priority review status for pegcetacoplan (Empaveli) to treat two rare kidney diseases that can lead to kidney failure. Up until now, there hadn’t been any drugs approved ...